Longevity Biotech: Investing in 21st Century Medicines
The Oxford Society of Ageing and Longevity and Oxford Venture Capital Network are excited to host Sebastian A. Brunemeier on Monday 16th November 18.30 on VC investments in the Longevity Biotech space!

Sebastian, an University of Oxford alumnus, has extensive experience in anti-ageing drug discovery and investing. An advisor to McKinsey & Company and Molecule GmbH, he has co-founded Cambrian Biopharma and Samsara Therapeutics and served as Principal as Apollo Health Ventures. 🚀
Sebastian will be introducing the science of anti-ageing technology, and providing insights into biotech and VC career paths in the longevity industry.

We look forward to seeing you on Monday! Everyone is welcome to register for the free ticket to the online event.
Date: 16 November 2020, 18:30
Venue: FREE Facebook Event, just click the link! https://www.eventbrite.com/e/longevity-biotech-investing-in-21st-century-medicines-tickets-128619563577
Speaker: Sebastian A. Brunemeier (Founder, Samsara Therapeutics; Principal, Apollo Ventures)
Organiser contact email address: ageingandlongevity@gmail.com
Hosts: Jack Harley (University of Oxford; Oxford Society of Ageing and Longevity Vice President), Anja Bitterwolf (University of Oxford; Oxford Society of Ageing and Longevity President)
Booking required?: Required
Booking url: https://www.eventbrite.com/e/longevity-biotech-investing-in-21st-century-medicines-tickets-128619563577
Cost: FREE
Audience: Public
Editor: Emily Monts